Stock APDN APPLIED DNA SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Applied DNA Sciences, Inc.

Equities

APDN

US03815U4094

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.37 USD -12.60% Intraday chart for Applied DNA Sciences, Inc. -36.32% -64.58%
Apr. 25 Applied DNA Sciences, Inc. Receives Contract by HDT Bio for Rapid Vaccine Development Program CI
Apr. 03 Certain Warrants of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024. CI

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 10.73 39.75 40.35 14.56 16.53 3.771 -
Enterprise Value (EV) 1 10.73 39.75 40.35 14.56 16.53 3.771 3.771
P/E ratio -0.92 x -2.33 x -2.6 x -1.22 x -1.59 x -0.34 x -0.41 x
Yield - - - - - - -
Capitalization / Revenue 1.99 x 20.6 x 4.47 x 0.8 x 1.24 x 0.75 x 0.46 x
EV / Revenue 1.99 x 20.6 x 4.47 x 0.8 x 1.24 x 0.75 x 0.46 x
EV / EBITDA - - - - - - -
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 60 257 374 644 683 863 -
Reference price 2 178.8 154.6 107.8 22.60 24.20 4.370 4.370
Announcement Date 12/12/19 12/17/20 12/9/21 12/14/22 12/7/23 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Net sales 1 5.389 1.932 9.028 18.17 13.37 5.019 8.17
EBITDA - - - - - - -
EBIT 1 -9.124 -12.54 -13.11 -13.97 -10.95 -14.21 -13.28
Operating Margin -169.31% -648.98% -145.26% -76.89% -81.94% -283.09% -162.57%
Earnings before Tax (EBT) 1 -8.617 -13.03 -14.28 -8.27 -10.02 -12.34 -14.75
Net income 1 -8.933 -13.03 -14.29 -8.378 -9.947 -12.87 -13.28
Net margin -165.76% -674.61% -158.25% -46.11% -74.41% -256.36% -162.57%
EPS 2 -193.8 -66.40 -41.40 -18.60 -15.20 -13.00 -10.60
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 12/12/19 12/17/20 12/9/21 12/14/22 12/7/23 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 3.04 4.166 6.147 4.296 3.559 5.263 4.408 2.917 0.7797 0.8912 0.951 1.179 1.998 1.4 1.7
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -4.457 -4.633 -1.994 -2.838 -4.369 -1.219 -2.704 -2.859 -4.171 -3.789 -3.612 -3.546 -3.262 - -
Operating Margin -146.63% -111.22% -32.44% -66.05% -122.76% -23.16% -61.35% -98% -534.9% -425.18% -379.76% -300.72% -163.29% - -
Earnings before Tax (EBT) 1 -4.508 -4.721 -1.76 -1.125 -0.6646 -3.844 0.5512 -3.114 -3.616 -1.13 -3.75 -3.745 -3.72 - -
Net income 1 -4.511 -4.722 -1.869 -1.124 -0.6632 -3.843 0.5883 -3.1 -3.592 -1.105 -3.612 -3.546 -3.262 - -
Net margin -148.4% -113.35% -30.4% -26.17% -18.63% -73.03% 13.35% -106.25% -460.7% -124.01% -379.76% -300.72% -163.29% - -
EPS 2 -10.40 -12.60 -4.600 -2.600 0.2000 -6.000 1.000 -4.800 -5.200 -1.800 -4.500 -3.700 -3.000 -5.800 -2.200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 12/9/21 2/10/22 5/12/22 8/11/22 12/14/22 2/9/23 5/11/23 8/10/23 12/7/23 2/8/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - 1.06 - - - - -
Capex / Sales - 55.07% - - - - -
Announcement Date 12/12/19 12/17/20 12/9/21 12/14/22 12/7/23 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Applied DNA Sciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.37 USD
Average target price
45 USD
Spread / Average Target
+929.75%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
APPLIED DNA SCIENCES, INC. Stock Applied DNA Sciences, Inc.
-64.58% 3.77M
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
+1.78% 5.41B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.29B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. APDN Stock
  4. Financials Applied DNA Sciences, Inc.